Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
HAMPTON, N.J., May 17, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic melanoma and the Phase 1 dose-escalation study of varlilumab and nivolumab in multiple solid tumors, will be presented in oral presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago. Information in the abstracts is current as of the time of submission in February 2017.
- Abstract #109: “A Phase 2 study of glembatumumab vedotin, an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.” Patrick A. Ott, M.D., Ph.D., Clinical Director of Dana-Farber Cancer Institute’s Melanoma Center and its Center for Immuno-Oncology, and Assistant Professor of Medicine at Harvard Medical School, will present results during the Clinical Science Symposium “Hitting the Target: Antibody-Drug Conjugates,” which begins on Monday, June 5, 2017 at 9:45 a.m. CDT.
- Abstract #3007: “Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.” Rachel E. Sanborn, M.D., co-director of the Providence Thoracic Oncology Program at Providence Cancer Center in Portland, Ore., will present results during the session “Developmental Therapeutics—Immunotherapy,” which begins on Monday, June 5, 2017 at 1:15 p.m. CDT.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Company Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected] Media Contact Dan Budwick Founder, 1AB Media (973) 271-6085 [email protected]
